We are live on ! Find out more
AI

Alphabet Inc Portfolio holdings

AUM $99.1B
1-Year Est. Return 124.46%
This Fund
S&P 500
This Quarter Est. Return
+16.04%
1 Year Est. Return
+124.46%
3 Year Est. Return
+326.82%
5 Year Est. Return
+231.24%
10 Year Est. Return
+1,201.66%
AUM
$4.02B
AUM Growth
+$1.44B
Cap. Flow
+$1.15B
Cap. Flow %
28.6%
Top 10 Hldgs %
94.04%
Holding
32
New
3
Increased
1
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
CME icon
CME Group
CME
+$1.03B
2
PL icon
Planet Labs
PL
+$84.5M
3
PAYP
PayPay
PAYP
+$66.1M
4
LIFE
Ethos Technologies Inc
LIFE
+$44.6M

Sector Composition

Rank Sector Weight
1 Technology 34.27%
2 Financials 26.67%
3 Industrials 24.53%
4 Healthcare 14.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CME icon
1
CME Group
CME
$94.8B
$1.03B 25.63%
+3,484,020
New +$1.03B
PL icon
2
Planet Labs
PL
$8.53B
$985M 24.53%
35,248,893
+3,306,252
+10% +$84.5M
ASTS icon
3
AST SpaceMobile
ASTS
$21.5B
$741M 18.46%
8,943,486
RVMD icon
4
Revolution Medicines
RVMD
$44B
$320M 7.97%
3,292,525
-52,577
-2% -$5.31M
ARM icon
5
Arm
ARM
$302B
$297M 7.39%
1,960,784
FRSH icon
6
Freshworks
FRSH
$3.27B
$130M 3.24%
16,206,643
PATH icon
7
UiPath
PATH
$7.8B
$78.1M 1.94%
7,034,337
TEM
8
Tempus AI
TEM
$9.39B
$70.1M 1.75%
1,551,102
PAYP
9
PayPay
PAYP
$10.4B
$66.7M 1.66%
+3,125,000
New +$66.1M
GTLB icon
10
GitLab
GTLB
$6.58B
$59M 1.47%
2,724,712
PRME icon
11
Prime Medicine
PRME
$556M
$57.6M 1.44%
16,562,498
LIFE
12
Ethos Technologies Inc
LIFE
$2.02B
$42.1M 1.05%
+3,770,156
New +$44.6M
MAZE
13
Maze Therapeutics
MAZE
$1.59B
$41.4M 1.03%
1,388,583
BBOT
14
BridgeBio Oncology
BBOT
$747M
$25.3M 0.63%
2,823,126
RLAY icon
15
Relay Therapeutics
RLAY
$4.31B
$15.6M 0.39%
1,564,173
-4,580
-0.3% -$41K
GLUE icon
16
Monte Rosa Therapeutics
GLUE
$1.34B
$11.3M 0.28%
684,275
-60,673
-8% -$1.16M
VERA icon
17
Vera Therapeutics
VERA
$2.36B
$9.71M 0.24%
241,264
SANA icon
18
Sana Biotechnology
SANA
$980M
$8.1M 0.2%
2,812,500
BEAM icon
19
Beam Therapeutics
BEAM
$2.84B
$7.66M 0.19%
321,604
LYEL icon
20
Lyell Immunopharma
LYEL
$360M
$5.88M 0.15%
293,256
OSCR icon
21
Oscar Health
OSCR
$8.41B
$5.53M 0.14%
481,988
FIG
22
Figma
FIG
$12.4B
$4.56M 0.11%
215,582
SPRO icon
23
Spero Therapeutics
SPRO
$73M
$2.08M 0.05%
889,979
HYPR icon
24
Hyperfine
HYPR
$94.8M
$971K 0.02%
898,720
AUTL
25
Autolus Therapeutics
AUTL
$562M
$964K 0.02%
698,262

Similar funds

Alphabet Inc's Q1 2026 Portfolio in Review

As of Q1 2026, Alphabet Inc held 32 positions worth $4.02B, up 56% from $2.58B the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Alphabet Inc deployed $1.15B of net new capital in Q1 2026, opening 3 new positions and adding to 1 existing holding. Its largest new stake was CME Group: 3,484,020 shares worth $1.03B.

By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 50% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Revolution Medicines, an estimated $5.31M trimmed.

  • Alphabet Inc's largest Q1 2026 buy was CME Group: 3,484,020 shares worth $1.03B.
  • Alphabet Inc added most to Planet Labs in Q1 2026, an estimated $84.5M increase.
  • Alphabet Inc's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $5.31M.
  • Alphabet Inc fully exited DexCom in Q1 2026, selling an estimated $68.8M.
  • Alphabet Inc's ten largest holdings make up 94% of its $4.02B portfolio in Q1 2026.
  • Alphabet Inc opened 3 new positions and closed 6 in Q1 2026.
  • Alphabet Inc's portfolio value rose 56% quarter-over-quarter to $4.02B.

Based on Alphabet Inc's 13F filing for Q1 2026, filed 8 May 2026.